Altimmune
Altimmune focused on the development of products to stimulate robust and durable immune responses for the prevention.
Launch date
Employees
Market cap
$505m
Enterprise valuation
$342m (Public information from Sep 2024)
Share price
$7.57 ALT
Gaithersburg Maryland (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 8.2m | 4.4m | (<1m) | <1m | 31.3m | 25.0m | 1.0m |
% growth | 41 % | (46 %) | (102 %) | (726 %) | 7236 % | (20 %) | (96 %) |
EBITDA | (54.2m) | (85.7m) | (84.9m) | (75.5m) | (99.1m) | (110m) | (121m) |
% EBITDA margin | (662 %) | (1943 %) | 124856 % | (17727 %) | (317 %) | (441 %) | (11858 %) |
Profit | (49.0m) | (97.1m) | (84.7m) | (88.4m) | (58.8m) | (137m) | (173m) |
% profit margin | (599 %) | (2201 %) | 124578 % | (20762 %) | (188 %) | (549 %) | (17021 %) |
EV / revenue | 51.0x | 82.3x | -10254.4x | 1101.6x | 14.7x | 10.7x | 374.2x |
EV / EBITDA | -7.7x | -4.2x | -8.2x | -6.2x | -4.7x | -2.4x | -3.2x |
R&D budget | 49.8m | 74.5m | 70.5m | 65.8m | - | - | - |
R&D % of revenue | 608 % | 1690 % | (103732 %) | 15446 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
N/A | N/A | IPO | |
$16.0m | Post IPO Equity | ||
$14.7m | Post IPO Equity | ||
N/A | $17.0m | Post IPO Equity | |
$3.7m | Grant | ||
Total Funding | $3.7m |
Related Content
Recent News about Altimmune
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Altimmune
EditACQUISITION by Altimmune Jan 2017
ACQUISITION by Altimmune Feb 2015